InvestorsHub Logo
icon url

enemem

11/27/13 1:29 PM

#39061 RE: drfreely #39060

thanks for sending it; let's hope for a reply.
icon url

food4thought

12/02/13 1:31 PM

#39062 RE: drfreely #39060

Thanks Dr. and sorry to hear of your father.

After hearing of your story and background, I don't feel quite as duped by good Ole Cortex and her touters as I did a mere minute ago.

It's a horrible shame to hear that a weathered bio-tech broker's misfortune and near financial ruin was primarily the result of a Cortex investment and the words of her leaders. His understanding of Bio-techs and their market, including their battles and means to exponential value as well as their instability, were obviously far more understood by him as it was a part of his daily rhetoric. His due diligence must have far superseded that of my willingness to believe the likes and notions of our board experts. It's a tragic story.

What's even more tragic however, is to hear that a family, with a higher understanding of Neurology backed by education and practice, had their hopes dwindled, dashed, mislead, and lost as a result of an FDA disapproval or of our company's leaders gross incompetence. Clearly you had a greater knowledge of your venture than most of us, and in so carried a much larger investment of hope which resulted in a far grander loss than all of us. The hopes of a Cortex molecule aiding in your father's recovery can never be recovered whereas my dollars can. Sad. It's a monumental shame what Cortex has cost so many of us in the I-hub community alone both financially and otherwise.

I can only hope that something does come of this investment before your story hits even closer to my home. I'm out nearly a half a million dollars, but the thought of a Cortex molecule saving someone close to me, yields far greater than this investment's monetary value ever could.

GLTY!
icon url

drfreely

02/03/14 3:29 PM

#39084 RE: drfreely #39060

Still no response from Management from my 11/12/13 query. Jeff Margolis seems to have taken the same approach to investor relations that served the previous management team so well. If there's an effort to commercialize any of the compounds I suppose its best to not get investors hopes up with press releases or communiques. Any increase in share price could prevent whoever's buying from continuing accumulating shares at this price, and might likewise prevent management from weaseling out of debt run up by Varney and friends. These are the only two potentially positive rationalizations for continuing to hold out hope.